Activation of a Yap1-mesenchymal-like program in β-cells during diabetes

A critical driver of type 2 diabetes is the failure of insulin-secreting β cells due to dysfunction and loss of cell number or identity. The signaling pathways that trigger these events remain unclear. Here, we identify an epithelial-to-mesenchymal (EMT)-like program that is activated in β cells to promote their loss with type 2 diabetes. This program is initiated in human and mouse β cells by the EMT transcription factor Yap1. While this protein is normally not present in β cells, Yap1 becomes upregulated in response to oxidative stress and impaired mitochondrial function. Chemical inhibition of Yap1 in islets reverses EMT-like activation while its overexpression in cells triggered the appearance of mesenchymal-like vimentin+ cells. Functionally, blocking Yap1 in isolated islets and in mice improves insulin secretion and alleviates diabetes. Taken together, we have identified a novel pathway of β-cell failure during type 2 diabetes, revealing a potential target for future diabetes treatment.

Authors

Institutions

Publication Details

Journal
Cell Reports
Published
2026-06-30
DOI
https://doi.org/10.1016/j.celrep.2026.117596
Primary Topic
Pancreatic function and diabetes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Activation of a Yap1-mesenchymal-like program in β-cells during diabetes

Wendy M. McKimpson, NEHAN HOQUE, Hitoshi Watanabe, Jinsook Son et al.
Cell Reports
Pancreatic function and diabetes
article

Activation of a Yap1-mesenchymal-like program in β-cells during diabetes

Wendy M. McKimpson, NEHAN HOQUE, Hitoshi Watanabe, Jinsook Son, Matthew Barter, April Y. Lee
article en

Abstract

A critical driver of type 2 diabetes is the failure of insulin-secreting β cells due to dysfunction and loss of cell number or identity. The signaling pathways that trigger these events remain unclear. Here, we identify an epithelial-to-mesenchymal (EMT)-like program that is activated in β cells to promote their loss with type 2 diabetes. This program is initiated in human and mouse β cells by the EMT transcription factor Yap1. While this protein is normally not present in β cells, Yap1 becomes upregulated in response to oxidative stress and impaired mitochondrial function. Chemical inhibition of Yap1 in islets reverses EMT-like activation while its overexpression in cells triggered the appearance of mesenchymal-like vimentin+ cells. Functionally, blocking Yap1 in isolated islets and in mice improves insulin secretion and alleviates diabetes. Taken together, we have identified a novel pathway of β-cell failure during type 2 diabetes, revealing a potential target for future diabetes treatment.

Cell ReportsVol. 45(7)
Emory University (US), Columbia University Irving Medical Center (US), Columbia University (US)
Russell Berrie Foundation, NIH Office of the Director, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases
Good health and well-being
Openalex Percentile: Top 8%
Pancreatic function and diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.